Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study by unknown
ORIGINAL RESEARCH
Clinical Effects of Liraglutide in a Real-World Setting
in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus
Working Group Study
Pedro Mezquita-Raya . Rebeca Reyes-Garcia . Oscar Moreno-Perez .
Javier Escalada-San Martin . Miquel A´ngel Rubio Herrera .
Martin Lopez de la Torre Casares
To view enhanced content go to www.diabetestherapy-open.com
Received: April 16, 2015 / Published online: June 9, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: A limitation with randomized
controlled trials is that, while they provide
unbiased evidence of the efficacy of
interventions, they do so under unreal
conditions and in a very limited and highly
selected patient population. Our aim was to
provide data about the effectiveness of
liraglutide treatment in a real-world and
clinical practice setting.
Methods: In a retrospective and observational
study, data from 753 patients with type 2
diabetes were recorded through an online tool
(eDiabetes-Monitor).
Results: Mean baseline glycated hemoglobin
(HbA1c) was 8.4 ± 1.4% and mean body mass
index (BMI) was 38.6 ± 5.4 kg/m2. After
3–6 months of treatment with liraglutide, we
observed a change in HbA1c of -1.1 ± 1.2%,
-4.6 ± 5.3 kg in weight and -1.7 ± 2.0 kg/m2
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in BMI (p\0.001 for all). Compared to baseline,
there was a significant reduction in systolic
blood pressure (-5.9 mmHg, p\0.001),
diastolic blood pressure (-3.2 mmHg,
p\0.001), LDL cholesterol (-0.189 mmol/l,
p\0.001) and triglycerides (-0.09 mmol/l,
p = 0.021). In patients switched from DPP-4
inhibitors, liraglutide induced a decrease of
-1.0% in HbA1c (p\0.001) and a reduction in
weight (-4.5 kg, p\0.001). In patients treated
with liraglutide as an add-on therapy to insulin
a decrease of -1.08% in HbA1c (p\0.001) and a
weight reduction of -4.15 kg (p\0.001) were
observed.
Conclusion: Our study confirms the
effectiveness of liraglutide in a real-life and
clinical practice setting.
Funding: Spanish Society of Endocrinology and
Nutrition.
Keywords: Effectiveness; Liraglutide; Real life;
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INTRODUCTION
Liraglutide is a GLP-1 receptor agonist (GLP1RA)
which induces a significant improvement in
glycemic control, body weight and
cardiovascular risk factors. Its use is cost-
effective when the clinical indicators and the
total costs associated with type 2 diabetes
mellitus (type 2 DM) management are
analyzed [1]. Current recommendations
prioritize the selection of antidiabetic
treatments with low risk of hypoglycemia, and
also recommend considering the effects of
antidiabetic drugs on weight when selecting a
treatment [2, 3]. The presence of hypoglycemic
events resulted in increased use of health-care
resources [4], so the selection of antidiabetic
treatment with a low risk of hypoglycemia may
result not only in an improvement in the
quality of life, but also in a reduction in costs
[4]. Considering these findings, in a recent
position paper from the Diabetes Mellitus
Working Group of the Spanish Society of
Endocrinology and Nutrition [5], the use of
GLP1RA as a second- or third-line therapy is
recommended in type 2 DM patients with
obesity due to its low risk of hypoglycemia
and its additional effects beyond the
improvement in glycated hemoglobin (HbA1c)
and weight.
The efficacy and safety of liraglutide both as
mono- and combination therapy have been
evaluated in the Liraglutide Effect and Action in
Diabetes (LEAD) program, where liraglutide
induced a decrease of HbA1c between 0.8%
and 1.5% [6–10]. In addition, liraglutide leads
to a reduction in weight and also in blood
pressure and lipids [11]. Due to its additional
effects on glycemic control, liraglutide is
associated with an improvement in life
expectancy and in quality-adjusted life
expectancy. It is also associated with a reduced
cost in diabetes-related complications, so it is
more cost-effective versus a DPP4 inhibitor [12].
A limitation with randomized controlled
trials is that, while they provide unbiased
evidence of the efficacy of interventions, they
do so under artificial conditions and in a very
limited and highly selected patient population.
Consequently, there is uncertainty regarding
whether the results obtained can be generalized
to the diverse patient populations encountered
in everyday clinical practice, and whether these
results can be generalized to standard care.
Reports about real-life effects of liraglutide
have been published recently [13–17].
However, some of them have included a scarce
number of patients treated with GLP1RA [13–
15]. Thus, the confirmation of these results in
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other countries and other populations is still
necessary. In this study, we provide data about
the effectiveness of liraglutide treatment in a
real-life and clinical practice setting in Spain.
METHODS
This is a multicenter, retrospective and
observational study. Data from type 2 DM
patients were recorded through an online tool
(eDiabetes-Monitor, available at www.
diabetesmonitor.es) designed for recording
data on clinical characteristics of type 2 DM
patients in clinical practice and for providing
tools (as dietetic and exercise recommenda-
tions) for the management of these patients.
Patients with type 2 DM, aged 18 years or older
and treated with GLP1RA, were included.
Exclusion criteria were type 1 diabetes and
refusal to provide informed consent. Due to the
retrospective design, the criteria for the selec-
tion of concomitant treatment, escalation of
the dose of GLP1RA and maintenance of the
dose were not specified in the study protocol
and were done prior to the inclusion of the
patients and according to routine clinical prac-
tice at the discretion of the investigator.
From June 2011 to February 2014, 753 patients
treated with GLP1RA were included. In the year
prior to the initiation of the study, only exenatide
and liraglutide were available in Spain. Thus, the
majority of the patients included in the study
(n= 740) were treated with liraglutide and 13
patients treated with exenatide were excluded
from the analysis. The main data from the study
were HbA1c, weight and diabetes treatment before
and after treatment with GLP1RA. Type 2 DM
patients with at least two visits registered in the
online tool (before the initiation of treatment and
3–6 months after that) and who had data about
changes of HbA1c, weight or both were selected
for analysis (n= 684). Patients in whom the
treatment for blood pressure or lipids was
modified were excluded. After that, 539 patients
had complete data of changes in lipid profile and
520 patients had complete data regarding
changes in blood pressure. Data on adverse
events including symptomatic hypoglycemia or
severe hypoglycemia were also collected.
The study was approved by the ethical review
board of the centers which took part in the
study and was done in compliance with the
ethic guidelines for research in humans. All the
procedures were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. All the participants in
the study provided informed consent after a full
explanation of the purpose of the study.
Informed consent was obtained from all
patients for being included in the study.
Statistical analysis
Data for continuous variables are presented as
mean ± standard deviation. Data for categorical
variables are presented as numbers and/or
percentages. Kolmogorov–Smirnov test was used
to test the normality of distribution of
continuous variables. Associations between
continuous variables were described by Pearson’s
coefficients. Comparisons of categorical variables
among groups were performed using Chi-square
test. Comparisons of continuous variables among
groups were performed using paired Student’s
t test or ANOVA when two or more of groups
were considered. Differences between variables
before and after treatment were assessed by
Student´s test for paired samples. The evaluation
of variables influencing changes in HbA1c and
weight after liraglutide treatment was done by
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t test when there were two conditions or by
ANOVA when tertiles. The selection of variables
was done according to clinical criteria and
considering previous data from literature. A
p value of less than 0.05 was considered
significant (two tailed). Data were recorded and
analyzed using SPSS version 18.0 software (SPSS
Inc, Chicago, IL, USA).
RESULTS
Baseline characteristics of type 2 DM patients
before starting liraglutide are shown in Table 1.
After the initiation of treatment with liraglutide
0.6 mg and after the dose escalation, 26.5% of
patients were treated with liraglutide 1.8 mg
and the remaining 73.5% with 1.2 mg. There
Table 1 Baseline characteristics of patients before starting liraglutide treatment
Number of patients % Mean – SD
Age (years) 738 55.6 ± 10.8
Male/females (%) 740 50.5/49.5














HbA1c (%) 725 8.4 ± 1.4
Weight (kg) 716 104.7 ± 19.3
BMI (kg/m2) 682 38.6 ± 5.4
SBP (mmHg) 637 141.4 ± 17.1
DBP (mmHg) 622 83.1 ± 11.1
HDL cholesterol (mmol/l) 647 1.14 ± 0.32
LDL cholesterol (mmol/l) 627 2.70 ± 0.84
Triglycerides (mmol/l) 676 2.42 ± 1.04
BMI body mass index, DBP diastolic blood pressure, OADs oral antidiabetic drugs, HbA1c glycated hemoglobin, SBP systolic
blood pressure, SD standard deviation
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were no differences in baseline HbA1c (8.4% vs.
8.5% for liraglutide 1.2 and 1.8 mg,
respectively, p = 0.430) or baseline weight (105
vs. 102.6 kg for liraglutide 1.2 and 1.8 mg,
respectively, p = 0.172). Likewise, no
differences were found when analyzing
changes in HbA1c (-1.09% and -1.05% for
liraglutide 1.2 and 1.8 mg respectively,
p = 0.730) or weight (-4.89 kg and -4.5 kg for
liraglutide 1.2 and 1.8 mg respectively,
p = 0.419) according to the dose of liraglutide.
After treatment with liraglutide, we observed
a change in HbA1c of -1.1 ± 1.2%,
-4.6 ± 5.3 kg in weight and -1.7 ± 2.0 kg/m2
in body mass index (BMI) (p\0.001 for all).
Liraglutide also induced a significant reduction
in systolic blood pressure (SBP)
(-5.9 ± 14.7 mmHg, p\0.001), diastolic blood
pressure (DBP) (-3.2 ± 10.7 mmHg, p\0.001),
LDL cholesterol (-0.189 ± 0.802 mmol/l,
p\0.001) and triglycerides (-0.09 ±
0.08 mmol/l, p = 0.021) (Table 2).
Eighty percent of patients achieved a
reduction of HbA1c and weight after liraglutide
treatment. The correlation between changes in
HbA1c and changes in weight showed a weak
relationship (r = 0.202, p\0.001). There were
no differences in HbA1c changes according to
BMI categories. No differences in liraglutide
effect (in terms of HbA1c or change in weight)
were found according to gender or diabetes
duration (Fig. 1). However, the decrease of
HbA1c was higher in patients in the highest
tertile of HbA1c (HbA1c C9.1%), and patients in
the lowest tertile of age (B50.8 years) or in the
highest tertile of BMI (C40.6 kg/m2)
experienced a higher reduction in weight
(Fig. 1). When analyzing liraglutide effects of
weight according to baseline BMI, the reduction
in weight was higher in patients with higher
baseline BMI (Fig. 2).
The decrease in HbA1c showed significant
differences according to the oral antidiabetic
drugs (OADs) added on to liraglutide (Fig. 3).
The reduction in weight was highest (-5.4 kg)
in patients treated with metformin and it was
significantly higher compared to patients
treated with secretagogues (sulfonylurea or
Table 2 Changes after liraglutide treatment
N Before After p
HbA1c (%) 648 8.4 ± 1.4 7.3 ± 1.3 \0.001
Fasting glucose (mmol/l) 597 10.00 ± 3.26 8.26 ± 2.81 \0.001
Weight (kg) 684 104.7 ± 18.7 100.1 ± 18.2 \0.001
BMI (kg/m2) 653 38.6 ± 5.4 36.9 ± 5.3 \0.001
SBP (mmHg) 520 140.0 ± 16.6 134.1 ± 15.2 \0.001
DBP (mmHg) 508 82.5 ± 10.8 79.3 ± 9.5 \0.001
HDL cholesterol (mmol/l) 527 1.15 ± 0.32 1.13 ± 0.31 0.312
LDL cholesterol (mmol/l) 512 2.71 ± 0.86 2.53 ± 0.76 \0.001
Triglycerides (mmol/l) 539 2.10 ± 1.04 2.01 ± 1.04 0.021
Results expressed as mean ± standard deviation
After excluding patients in whom the treatment for blood pressure or lipids was modiﬁed, 539 patients had complete data of
changes in lipid proﬁle and 520 patients had complete data regarding changes in blood pressure
BMI body mass index, DBP diastolic blood pressure, HbA1c glycated hemoglobin, SBP systolic blood pressure
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glinide) or secretagogues plus metformin
(Fig. 3). The percentage of patients reaching
a composite end point (HbA1c \7% and a
decrease in weight without hypoglycemia)
after liraglutide treatment was significantly
higher in patients treated with metformin and
liraglutide (54.8%) compared to patients with
added liraglutide to metformin plus
secretagogues (26%), or patients treated with
liraglutide in combination with metformin
plus basal insulin (24.2%) (p\0.05) (Fig. 3). In
patients treated with liraglutide as
monotherapy, a reduction of -0.87% in
HbA1c and a decrease of -4.46 kg was
observed.
When we analyzed composite end points
after liraglutide treatment, 48.3% of patients
achieved an HbA1c of 7% or less, 59.4% reached
a weight reduction higher than 3% and in
28.1% both parameters were achieved (Fig. 4).
Besides, in 36.3% of patients the reduction in
weight was higher than 5%, and 9.2% of
patients lost more than 10% of their initial
weight. We also observed an improvement in
the control of blood pressure and LDL
cholesterol. In addition, 27.7% of patients
reached an end point of controlled SBP and
DBP and LDL\2.59 mmol/l (Fig. 4).
In patients previously treated with DPP-4
inhibitors, liraglutide in combination with
Fig. 1 Changes in HbA1c and weight after liraglutide
treatment in different subgroups of patients. Data are mean
(point) and 95% conﬁdence interval. Age and diabetes
duration is in years. 1 1st tertile (below: tertile’s upper
limit), 2 2nd tertile, 3 3rd tertile (below: tertile’s lower
limit), BMI body mass index (kg/m2), F female, HbA1c
glycated hemoglobin, M male. p values are shown for t test
when there were two conditions or for ANOVA when
tertiles
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OADs decreased HbA1c by 1.0% (p\0.001) and
also induced a reduction of -4.5 kg (p\0.001)
(Fig. 5). In patients in whom DPP4 inhibitors
were maintained after the initiation of
liraglutide, HbA1c decreased -1.28% and the
weight reduction was -5 kg. However, there
were no significant differences in the reduction
of HbA1c when DPP-4 inhibitors were switched
off or maintained. In patients treated with
insulin ± OADs, after add-on of liraglutide a
reduction of -1.08% in HbA1c and -4.15 kg was
observed (p\0.001 for both) (Fig. 5). The
change in HbA1c and weight was higher when
insulin and liraglutide were added to previous
treatment (HbA1c -1.43%, weight -7 kg)
compared to switching from insulin to
liraglutide ± OADs (HbA1c -0.68%, weight
-4.26 kg) (Fig. 5).
Regarding adverse effects, clinically
significant gastrointestinal symptoms were
recorded in seven patients. Only one patient
discontinued the treatment, and the other six
patients remained on treatment with a slower
dose escalation. However, 68 patients (10%)
who started liraglutide did not complete the
two visits. We have no data regarding the
reason for discontinuation, and we are aware
that in many of these patients the reason may
have been side effects, which will result in a
similar percentage of side effects as have been
reported in clinical trials. Hypoglycemic events
were reported in 7.8% of patients. None of them
were severe hypoglycemia. Hypoglycemic
events were reported in 10.6% of patients
treated with insulin and liraglutide, compared
to 15.2% of patients treated with secretagogues
and liraglutide (p = 0.369). In patients treated
with liraglutide and metformin, the frequency
of hypoglycemia was lower (1.6%) compared to
patients treated with insulin or secretagogues
(p\0.001 for both).
DISCUSSION
This study confirms the effectiveness of
treatment with liraglutide in Spanish type 2
DM patients in a real-world setting. These data
demonstrated a -1.1% mean reduction in
HbA1c and a decrease of -4.6 kg in weight.
Treatment with liraglutide allows many patients
to reach composite end points, with HbA1c of
less than 7% and a weight reduction higher
than 3%. This was observed in 28.1% of patients
after liraglutide treatment.
Fig. 2 Percentage of patients and changes in HbA1c and
weight across baseline body mass index categories after
liraglutide treatment. HbA1c glycated hemoglobin.
*p\0.001 (Chi-square test)
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The reduction in HbA1c in our study was
somewhat lower than the effect reported in the
LEAD trials, which may be explained by a longer
duration of the disease (10 ± 6 years) in the
present study, compared to 7.7 years in LEAD
studies. However, when analyzing real-life
studies, the results of the present study are in
line with previous data [13, 14] showing a
reduction in HbA1c between -1.23% and
-1.5%, and a mean weight reduction between
-2.9 and -4 kg. We did not find differences in
HbA1c or weight changes according to the dose
of liraglutide, which is in contrast to previous
results from LEAD trials [6, 8]. The presence of
uncontrolled variables may have influenced
these results, so no definite conclusions
regarding the dose can be inferred from our data.
In the LEAD program, weight changes were
between -1.38 and -3.75 kg [6–10]. The mean
weight reduction in this study was higher
(-4.6 kg) which may be explained by higher
mean weight compared to LEAD studies.
However, these results confirm previous
retrospective data from the USA [17], where a
reduction in weight between 1.5 and 4 kg and a
decrease of HbA1c between 0.95 and 1.02% were
observed.
We did not find differences in HbA1c
reduction according to diabetes duration or
the number of OADs. However, after treatment
with liraglutide as monotherapy, the reduction
in HbA1c and weight was in line with results
from LEAD 3 study, where liraglutide
monotherapy for 2 years provided significant
effect on glycemic control and body weight
compared with glimepiride monotherapy, at a
lower risk of hypoglycemia [18]. In addition, in
our study changes in BMI after liraglutide were
Fig. 3 Percentage of patients achieving glycemic control
and weight reduction without hypoglycemia and changes in
HbA1c and weight according to the oral antidiabetic
treatment associated with liraglutide. HbA1c glycated
hemoglobin, MET metformin, SEC secretagogue
(sulfonylurea or repaglinide), TZD thiazolidinedione. Top
a: *p\0.05 (Z test) vs. metformin monotherapy. Below b:
*p\0.05 (t test) vs. metformin monotherapy
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higher in patients treated with metformin, and
the percentage of patients reaching the
composite end point of decreased HbA1c and
weight without hypoglycemia was highest in
patients treated with metformin. This may
indicate some benefits of an early initiation of
liraglutide. However, the absence of drugs
inducing weight gain, as the secretagogues,
may have influenced these results. Moreover,
the weak correlation between HbA1c changes
and weight reduction and the absence of
differences in HbA1c reduction according to
previous OADs are of clinical relevance. Thus,
even in the case of limited HbA1c effectiveness,
a clinically significant reduction in weight and
consequently in diabetes-related complications
risk may be expected.
In the present study after liraglutide
treatment, a significant increase in the
percentage of patients reaching a composite
end point of controlled SBP, DBP and LDL
below 2.59 mmol/l (from 17.4% to 27.7%) was
observed. Thus, liraglutide allowed more
patients to achieve an adequate control of
cardiovascular risk factors and may result in
reduced cardiovascular risk, although this
hypothesis must be confirmed in prospective
clinical trials which are currently ongoing.
In type 2 DM patients previously treated
with DPP-4 inhibitors, switching to liraglutide
induced an improvement in HbA1c and weight
in line with previous real-life studies [16, 19].
According to this, switching patients who are
inadequately controlled with DPP-4 inhibitors
to liraglutide is an effective strategy. There were
no significant differences in weight or HbA1c
reduction in patients who remained on DPP4
inhibitors during liraglutide treatment,
compared to patients who switched to
liraglutide from DPP4 inhibitors. Violante and
Fig. 4 Percentage of patients achieving glycemic control,
weight reduction and control of cardiovascular risk factors
after treatment with liraglutide. DBP diastolic blood
pressure, HbA1c glycated hemoglobin, SBP systolic blood
pressure, WR weight reduction. *p\0.001 for the com-
parison between baseline and after treatment (Chi-square
test)
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colleagues showed that the addition of
exenatide twice daily to patients inadequately
controlled with sitagliptin and metformin
provided better glycemic control than
switching to exenatide, although the longer
half-life of liraglutide compared to exenatide
may explain this discrepancy [20]. Moreover,
when considering the additional efficacy
observed after the combination of exenatide
and sitagliptin (HbA1c reduction of -0.3%) and
the cost of the treatment, it may be of limited
utility.
24.2% of patients treated with metformin,
basal insulin and liraglutide reached a
composite end point of HbA1c \7% and
reduction in weight without hypoglycemia. In
the meta-analysis performed by Zinman and
colleagues [21], the percentage of patients
reaching this composite end point at 26 weeks
was 15% for patients treated with glargine. The
decrease in HbA1c and weight was higher in
patients for whom liraglutide was added to
insulin ± OADs and patients for whom
liraglutide and insulin were added to previous
treatment, compared to patients who switched
from insulin ± OADs to liraglutide ± OADs.
After the initiation of insulin, an increase in
hypoglycaemic episodes and weight occurs [22],
which may influence cardiovascular risk and is
often a concern both for patients and
physicians. Moreover, patients treated with
insulin often do not achieve an adequate
HbA1c [23]. Thus, our data indicates the utility
of liraglutide in insulin-treated patients.
Our study has several limitations. First, due
to the observational design, study visits were
not strictly specified and the time between
liraglutide initiation and laboratory data was
more flexible. Secondly, clinical events and
adverse events may not have been fully
reflected by the study. Besides, due to the
retrospective design, only patients with at least
two visits (before and after liraglutide
treatment) were included in the study, and
probably the majority of patients with intense
gastrointestinal adverse events were
discontinued on their last visit. This fact
probably has influenced the low rate of
gastrointestinal symptoms reported in the
present study, which is lower than that in
previous data. Moreover, if we consider that in
many of the 10% of patients who did not
complete the two visits, the reason may be due
to secondary effects, the percentage is similar to
previous data from observational studies. In
addition, the absence of data from patients with
early withdrawal from liraglutide treatment
Fig. 5 Changes in HbA1c and weight after liraglutide
treatment according to DPP4 inhibitor and insulin
treatment variations. Data are mean (point) and 95%
conﬁdence interval. HbA1c glycated hemoglobin, OADs
oral antidiabetic drugs. p values are shown for t test
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may result in better glycemic and weight results
and also in less adverse events, compared to
those that would take place in the whole
population of liraglutide-treated patients.
Finally, due to the heterogeneity of patient’s
characteristics, results from between group’s
comparisons should be interpreted with
caution. On the other hand, the strength of
our study is the size of the sample, which was
larger than that of some of the previous
observational studies. This may improve the
reproducibility of the results when applying
them to the general population.
CONCLUSION
Our study confirms the effectiveness of liraglutide
in a real-world setting. In our cohort of patients
with type 2 DM, treatment with liraglutide
induced a significant reduction in HbA1c,
weight, lipids and blood pressure. Our results
confirm the benefits observed in clinical trials.
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